Imugene hails supply partnership with Merck KGaA and Pfizer

Imugene Limited’s Leslie Chong speaks to Proactive following the news of clinical trial supply deal with Merck KGaA, Darmstadt, Germany, and Pfizer Inc to evaluate the safety and efficacy of Imugene’s HER-Vaxx, in combination with avelumab, in patients with HER-2 positive gastric cancer.
HER-Vaxx is Imugene’s B-cell activating immunotherapy, which will be assessed in conjunction with avelumab, an immune checkpoint inhibitor targeting PD-L1 which is marketed as BAVENCIO® and co-developed and commercialised by Merck KGaA and Pfizer.